Classimed logo

CLASSIF1 Classification

Pretherapeutic Identification of High Risk AML Patients

< fig.4      fig.5: Prognostic Disease Classification Masks

fig.5 prognostic disease classification masks

- Patient stratification provides prognostic information for the future of patient groups or cohorts (L1) but no individualized outcome prediction (*external link L2) as obtained by data pattern classification.. (fig.3, fig.4).
- Prognostic and individually predictive data patterns show only partial identity (CD4, CD11b, CD13, HLA-DR), characterizing the difference between group prognostic stratification (fig.6) and individualized predictions.

Literature References:
*external link L1. Repp R, Schaekel U, Helm G, Thiede C, Soucek S, Pascheberg U, Wandt H, Aulitzky W, Bodenstein H, Kuse R, Link H, Ehninger G, Gramatzki M and AML-SHG Study Immunophenotyping is an independent factor for risk stratification in AML. Cytometry 53B:11-19, (2003)
L2. Valet G, Repp R, Link H, Ehninger G, Gramatzki M and SHG-AML study group. Pretherapeutic identification of high risk acute myeloid leukemia (AML) patients from immunophenotype, cytogenetic and clinical parameters. Cytometry 53B:4-10, (2003)

© 2024 G.Valet
last update: Jun 03,2022
first display: Mar 31,2003